Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) - Total Liabilities
Based on the latest financial reports, Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) has total liabilities worth $3.45 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Cuprina Holdings (Cayman) Limited Class to track the company's year-over-year net asset growth rate.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
UK | GBX4.06 Million |
|
Global Health Ltd
AU:GLH
|
Australia | AU$6.46 Million |
|
CVC Income & Growth Limited
LSE:CVCG
|
UK | GBX316.86K |
|
CDT Environmental Technology Investment Holdings Limited ordinary shares
NASDAQ:CDTG
|
USA | $8.34 Million |
|
Fuller Smith & Turner
LSE:FSTA
|
UK | GBX292.50 Million |
|
Transition Evergreen
PA:EGR
|
France | €56.53 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | Rs531.88 Million |
|
Bridge Saas Ltd
AU:BGE
|
Australia | AU$1.67 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Cuprina Holdings (Cayman) Limited Class worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (2021–2025)
The table below shows the annual total liabilities of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.45 Million | -44.41% |
| 2024-12-31 | $6.20 Million | +38.41% |
| 2023-12-31 | $4.48 Million | +39.46% |
| 2022-12-31 | $3.21 Million | +96.41% |
| 2021-12-31 | $1.64 Million | -- |
About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collag… Read more